The overall goal of the Experimental Therapeutics (ET) Program is the development of novel mechanism-driven anticancer therapies through an improved understanding of molecular pathways in normal cells and cancer cells and insights into mechanisms involved in drug resistance. To achieve this goal, the Program is organized into three interacting (interactive) research themes that span the spectrum of basic, translational and clinical science: Angiogenesis and Metastasis, Cell Survival and Drug Resistance, and Gene expression and Molecular Targets, In addition to these themes, the ET program has two overarching missions. First, to be the conduit for bringing scientific findings from other CCSG programs into the clinic. As such, the Phase I and ET Drug Development expertise provides an Institute-wide resource for drug discovery methods, preclinical efficacy studies, IND-enabling toxicology, IND submission support, PK/PD modeling, and clinical trial conduct and management. Secondly, the ET Program is committed to training the next generation of clinician-scientists with expertise in all phases of drug development. The Program is co-led by Drs. Alex Adjei, and William Cance. Dr. Adjei is an internationally recognized clinician scientist with expertise in drug development, phase l/ll clinical trials of novel cancer agents and lung cancer. As the director of the Phase I unit, his leadership has been instrumental in building the drug development team. His research interests are in targeting cell survival pathways for cancer therapy in lung cancer. Dr. Cance is a highly regarded cancer surgeon and translational scientist with long-standing interests in angiogenesis and tumor metastasis. He has an ROl-funded program evaluating FAK inhibitors for cancer therapy. The complementary expertise of the leadership team facilitates the integration of basic, translational and clinical science by providing venues to promote discussion of research, formation of basic science-clinical partnerships, and providing guidance to membership for available research funding. The Program consists of 25 members from 7 departments. 541 publications are the product of ET members (2008-2013), with 23% of the publications as intra-programmatic and 22% inter-programmatic. 34 publications were in journals with Impact Factor >10. The ET Program has translated recent preclinical findings into 12 ongoing clinical trials. There were 326 patients enrolled to treatment trials in CY2012 compared with 453 patients in CY2008. Current annual total peer-reviewed Program funding is $10.3M, of which $9.3M is from NCI, and the total extramural research funding is $14.4M.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Zhao, Zhiguo; Wen, Wanqing; Michailidou, Kyriaki et al. (2016) Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control 27:679-93
Goossens, Maria E; Isa, Fatima; Brinkman, Maree et al. (2016) International pooled study on diet and bladder cancer: the bladder cancer, epidemiology and nutritional determinants (BLEND) study: design and baseline characteristics. Arch Public Health 74:30
Clyde, Merlise A; Palmieri Weber, Rachel; Iversen, Edwin S et al. (2016) Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. Am J Epidemiol 184:579-589
Wilton, John; Kurenova, Elena; Pitzonka, Laura et al. (2016) Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. Eur J Drug Metab Pharmacokinet 41:55-67
Sexton, Sandra; Tulowitzki, Ryan; Jones, Craig A et al. (2016) Involvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model. Clin Exp Nephrol 20:162-8
Shafirstein, Gal; Battoo, Athar; Harris, Kassem et al. (2016) Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc 13:265-75
Pharoah, Paul D P; Song, Honglin; Dicks, Ed et al. (2016) PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 108:
Austin, David C; Strand, Douglas W; Love, Harold L et al. (2016) NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate 76:1004-18
Chinnam, Meenalakshmi; Wang, Xiaoling; Zhang, Xiaojing et al. (2016) Evaluating Effects of Hypomorphic Thoc1 Alleles on Embryonic Development in Rb1 Null Mice. Mol Cell Biol 36:1621-7
Klinkebiel, David; Zhang, Wa; Akers, Stacey N et al. (2016) DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. Mol Cancer Res 14:787-94

Showing the most recent 10 out of 1099 publications